You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm also increased the size of its Series G preferred shares offering and will use the funds to develop tests for guiding the use of cancer immunotherapy.
Perceptive Credit Holdings has agreed to provide the company with the loan, which CareDx said it will use to repay outstanding debt.
The loan can be funded at Invitae's option during the second quarter of 2018 and will provide flexibility as the firm grows its genome network.
The firm said it expects to finance the construction of a clinical lab and related facilities, as well as additional development of a 46-acre campus.
The company raised its previous €130 million offering of senior notes to €155 million. It also increased its term loan syndication to €190 million.
The company immediately borrowed $255 million to pay part of the $680 million price tag for Alere's MeterPro cardiovascular and toxicology business and its BNP assay business.
The firm said that it expects to use the proceeds of the senior notes offering to contribute to retirement of remaining convertible notes.
The company received a $1.2 million loan to support its American subsidiary, and a $294,000 grant to help pay for a new R&D facility in the Walloon region of Belgium.
The company amended and restated an existing senior revolving credit facility in the principal amount of $1.0 billion with the ability to increase it by up to $350 million.
The firm said it may use the loans to finance its $1.3 billion acquisition of Euroimmun Medical Laboratory Diagnostics.